{
  "docId": "019dd923-5de0-76bd-a169-83187257f35b",
  "docSlug": "5d146414b5cc38c9",
  "documentTitle": "Vaccines & Therapeutics Outlook Part I: Timelines and Success Factors",
  "authorId": "BCG",
  "authorName": "BCG",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 11,
  "pageCount": 34,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "industry_trends",
  "function": "establish_context",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "The slide highlights the unprecedented nature of the COVID-19 vaccine development effort as of August 2020.",
  "elementsJson": [
    "headline_text",
    "bar_chart_vertical",
    "bullet_list",
    "paragraph"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5de0-76bd-a169-83187257f35b/11",
  "deckHref": "/decks/019dd923-5de0-76bd-a169-83187257f35b",
  "deckJsonHref": "/decks/019dd923-5de0-76bd-a169-83187257f35b.json",
  "deckAnchorHref": "/decks/019dd923-5de0-76bd-a169-83187257f35b#slide-11",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Large funding commitments by governments & global institutions toward vaccine development: US ($5.8B), Germany ($1.0B), UK ($0.5B), etc.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-fefb-728e-ad95-bd04258eb0d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Comparison of # of vaccine candidates in clinical and pre-clinical trials across diseases",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "164358b3-ed41-48bc-8f2b-ca51ab7cd49c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "list",
      "text": "Traditional technologies: Protein sub-unit, Whole virus. Novel technologies: Viral vector, Nucleic acid.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60cdb753-4d26-415d-9c01-3b163724196e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Number of vaccine candidates: 207",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-fefb-728e-ad95-c169d3b304e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "paragraph",
      "text": "Large funding commitments by governments & global institutions toward vaccine development: US ($5.8B), Germany ($1.0B), UK ($0.5B), etc.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e41b516-e8fb-4426-b6d9-91d4d087a451",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: EvaluatePharma, WHO, Milken Institute, Research Professional News, Bloomberg, Press search, BCG",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ed8b376-f284-4f5a-bc0c-2fcd2003e115",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "COVID-19 vaccine | An unprecedented response globally on scale and speed of R&D efforts",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d675878-3ff6-4dca-b5a9-b9bce3dc908c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Scarcity",
      "slug": "scarcity",
      "agent": "Storyteller",
      "layer": "block",
      "matchId": "019dd95a-163f-72bd-8a09-0ce5a700a105",
      "evidence": "Word unprecedented positions the timeline as a rare window.",
      "confidence": 55
    },
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "019dd95a-163f-72bd-8a09-07362fada6de",
      "evidence": "Title states unprecedented response globally on scale and speed.",
      "confidence": 85
    },
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "453332a9-49e6-4b25-b400-3ca082c55f48",
      "evidence": "The slide features a bar chart comparing the number of vaccine candidates in clinical and pre-clinical trials across diseases.",
      "confidence": 0.7
    },
    {
      "name": "Concrete Language",
      "slug": "concrete-language",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "019dd95a-163f-72bd-8a09-0b23cee18c29",
      "evidence": "Specific dollar amounts: US $5.8B, Germany $1B, UK $0.5B.",
      "confidence": 80
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 9,
      "beatId": "019dd95a-0702-74a3-87e3-afd1671a9591",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Vaccines/therapeutics as path; timelines, fast movers, success factors",
      "position": 3,
      "confidence": 78,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 14,
      "from": 4,
      "beatId": "019dd95a-0702-74a3-87e3-b9ab3fe072a9",
      "arcName": "The Triple Take",
      "arcSlug": "triple-take",
      "beatName": "The Facts (What)",
      "beatSlug": "triple-take-the-facts-what",
      "evidence": "Snapshot, epidemic curves, vaccine pipeline, timelines",
      "position": 1,
      "confidence": 65,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 9,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "019dd95a-088c-724c-b30f-be0320e082a4",
      "evidence": "p11-12 frame unprecedented response and 12-18 month window; p13-14 detail fast movers and Q2 2021 distribution.",
      "position": 3,
      "objective": "Establish unprecedented vaccine response and timeline opportunity",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 75,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}